1methotrexate MOA
folate antimetabolite
2methotrexate brand
Otrexup
3methotrexate frequency
single weekly dose
4methotrexate monitoring
CBC, LFTs, Screen, chest x ray
5methotrexate main advantage
most efficacious non-biologic, considered first line treatment for most patients.
6leflunomide MOA
inhibits pyrimidine synthesis
8leflunomide frequency
daily
9leflunomide monitoring
none
10leflunomide main advantage
No myelosuppression, similar efficacy to moderate doses of methotrxate. May be used in place of or in combination with MTX.
11hydroxychloroquine MOA
unknown
12hydroxycloroquine brand
Plaquenil
13hydroxychloroquine frequency
daily or BID
14hydroxychloroquine monitoring
ophthalmic exam
15hydroxychloroquine main advantage
no myelosuppressive or hepatic adverse events, so it can be safer than the alternatives. However, lower efficacy.
16sulfasalazine MOA
metabolized to sulfapyridine and 5-ASA
17sulfasalazine brand
Azulfidine
18sulfasalazine frequency
BID
19sulfasalazine monitoring
CBC
20sulfasalazine main advantage
can be used in patients with mild disease or used in combination with MTX. May cause yellow-orange discoloration of bodily fluids, and should not be used in patients who have a sulfa allergy or are hepatically impaired.